Biopharmaceuticals
HIV/AIDS
News Release - December 22, 2009
Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' New Drug Application (NDA) for Efavirenz Tablets
Source: Mylan
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.